Simeprevir: 5 agencies, 2014–2019
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused simeprevir: all 6 decisive outcomes across 4 agencies were positive or positive with restrictions.
The record spans 4.3 years, opening at SMC (Scotland) on 13 Oct 2014 and running to 27 Feb 2019.
No assessment is on file from HAS (France), AWMSG (Wales), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for simeprevir, 2 were withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
Nothing has been added since 2019; on this evidence the file is dormant.
3 distinct indication wordings are recorded for simeprevir by the agencies that label one in English (PBAC and SMC).
2 of these 8 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
SMC (Scotland) was first to assess simeprevir, on 13 Oct 2014; PHARMAC (New Zealand) did not open a file until 11 Aug 2016 — a moderate spread of 1.8 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 4 years in total.
Restriction is doing real work here: 2 of 6 decisive outcomes narrowed simeprevir to a subgroup rather than accepting or refusing it outright, at TLV (Sweden).
3 of the 5 agencies here assessed simeprevir more than once, CONITEC (Brazil) most often at 2 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 5 of the 18 agencies here have assessed simeprevir.
The full ledger for simeprevir reads 4 recommended, 2 withdrawn and 2 restricted.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CONITEC (Brazil) | 27 Feb 2019 | Tratamento da hepatite C | excluded from SUS | source |
| PHARMAC (New Zealand) | 11 Aug 2016 | Chronic hepatitis C, genotype 1 | PTAC advice: Cost Neutral · decision reached | source |
| PBAC (Australia) | 2016 | Chronic hepatitis C (CHC) infection | The PBAC recommended to change the current Section 100 (Highly Specialised Drug Program) p… | source |
| TLV (Sweden) | 16 Jun 2015 | Olysio kvarstår i högskostnadsskyddet för de svårast sjuka | restricted subsidy | source |
| SMC (Scotland) | 13 Oct 2014 | In combination with other medicinal products for the treatment of chronic hepatitis C in adult patients. | withdrawn | source |
3 further decisions for simeprevir, across 3 agencies, are not shown here. They link to 1 further source document.
Related molecules
- ombitasvir / paritaprevir / ritonavir — divergent outcome (recommended vs restricted) on a shared indication
- sofosbuvir — same ATC class J05A — Antivirals
- letermovir — same ATC class J05A — Antivirals
- raltegravir — same ATC class J05A — Antivirals
- cabotegravir — same ATC class J05A — Antivirals
- tenofovir — same ATC class J05A — Antivirals
Coverage: 8 decisions for simeprevir from 5 agencies, 2014 to 2019. Data to 7 Sep 2026. ATC class J05A — Antivirals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.